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Abstract
Myeloproliferative neoplasms (MPN) are a diverse group of chronic hematological disorders that involve unregulated
clonal proliferation of white blood cells. Sevearl of them are associated with mutations in receptor tyrosine kinases or
cytokine receptor associated tyrosine kinases rendering them independent of cytokine-mediated regulation. Classically
they have been broadly divided into BCR-ABL1 fusion + ve (Ph + ve) or –ve (Ph-ve) MPNs. Identification of BCR-
ABL1 tyrosine kinase as a driver of chronic myeloid leukemia (CML) and successful application of small molecule
inhibitors of the tyrosine kinases in the clinic have triggered the search for kinase dependent pathways in other
Ph-ve MPNs. In the past few years, identification of mutations in JAK2 associated with a majority of MPNs raised
the hopes for similar success with specific targeting of JAK2. However, targeting JAK2 kinase activity has met with
limited success. Subsequently, mutations in genes other than JAK2 have been identified. These mutations specifically as-
sociate with certain MPNs and can drive cytokine independent growth. Therefore, targeting alternate molecules and path-
ways may be more successful in management of MPNs. Among other pathways, phosphatidylinositol −3 kinase (PI3K) has
emerged as a promising target as different cell surface receptor induced signaling pathways converge on the
PI3K signaling axis to regulate cell metabolism, growth, proliferation, and survival. Herein, we will review the
clinically relevant inhibitors of the PI3K pathway that have been evaluated or hold promise for the treatment of
Ph-ve MPNs.
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Introduction
The term ‘myeloproliferative disorders’ has historically been
applied to a group of four hematological diseases – 1) poly-
cythemia vera (PV), 2) essential thrombocythemia (ET), 3)
primary myelofibrosis (PMF) and 4) chronic myeloid
leukemia (CML). This grouping was based on some of
the clinical and biological similarities in patients due to
clonal proliferation of hematopoietic progenitor cells
and excessive production of blood cells of different lin-
eages. With a better understanding of the molecular
events underlying these malignancies, the World Health
Organization (WHO) has reclassified them on the basis of
histology, translocations and mutations in protein tyrosine
kinases [1, 2]. These have helped in diagnosis and conse-
quent treatment decisions. Proliferative disorders associated
with myeloid cells including the granulocytic, monocytic/
macrophage, erythroid, megakaryocytic, and mast cells have
been grouped under 5 broad categories: (1) myeloprolifera-
tive neoplasms (MPN), (2) myeloid and lymphoid neo-
plasms associated with eosinophilia and abnormalities of
platelet derived growth factor receptor (PDGFR) or fibro-
blast growth factor receptor (FGFR), (3) myelodysplastic/
myeloproliferative neoplasms (MDS/MPN), (4) myelodys-
plastic syndrome (MDS) and, (5) Acute myeloid leukemia
and related neoplasms. The term ‘myeloproliferative neo-
plasms’ has replaced the older ‘myeloproliferative disorders’.
In addition to the four classical MPNs, PV, ET, PMF and
CML (Ph + ve), this group now also includes chronic neu-
trophilic leukemia (CNL), chronic eosinophilic leukemia
not otherwise specified (CEL-NOS), mastocytosis and un-
classifiable myeloproliferative neoplasms. For the purpose
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of this review we will focus on the Ph –ve MPNs as defined
under the first category of WHO classification since others
have been reviewed elsewhere [3, 4].
As per the estimates for 2008–2010, there were 44–57
and 38–57 PV and ET patients per 100,000 people re-
spectively, while 4–6 PMF patients per 100,000 people
in the United States [5]. MF can be primary or develop
subsequent to PV/ET. Though its prevalence rate is low,
it is the most disabling of the MPNs. No reliable esti-
mates are available for the prevalence rate of mastocyto-
sis, CNL and CEL. The chronic nature of MPNs,
absence of a defined therapeutic regimen and potential
for transformation to acute myeloid leukemia makes
them a challenge. Until a few years back, there was no
drug that was approved by Food and Drug Administra-
tion (FDA) for the treatment of MPN. Therefore, the
treatment options for these patients were mostly empir-
ical [6]. A kinase dependent oncogenic pathway essential
for the survival of leukemic cells was identified in
chronic myeloid leukemia (CML). The inhibition of the
BCR-ABL1 kinase led to significant enhancement in the
survival of CML patients [7]. These results along with
other studies have contributed to the concept of ‘oncogene
addiction’. It is believed that cancer cells are addicted to the
oncogene and targeting of the crucial oncogenes/pathways
can lead to elimination of cancer cells. However, results
from the clinic have demonstrated that cancer cells can ac-
quire additional mutations and activate compensatory path-
ways that eventually lead to drug resistance and disease
relapse [8].
Genetic basis of MPNs
Discovery of JAK2V617F mutation in a majority of Ph-ve
MPN patients and the ability of this mutant protein to
recapitulate a MPN phenotype in experimental models
has been a turning point in our understanding of clas-
sical Ph-ve MPNs [9–11]. It established a genetic basis
for the classical Ph-ve MPNs. In addition to becoming
an integral part of diagnosis, it has also opened up the
field for selective targeting of the kinase pathway in
treatment of Ph-ve MPNs. Since then several additional
mutations have been identified that specifically associate
with different myeloid neoplasms [12, 13]. These include
components of the cytokine signaling, regulators of the
chromatin structure and RNA splicing in addition to
cytogenetic abnormalities with uniparental disomy of
chromosome 9p being the most frequent (~35 %) aber-
ration. The driver mutations conferring a clonal prolifer-
ative advantage arise in the adult hematopoietic stem
cell and early progenitor compartments. Acquisition of a
combination of mutations is required for progression
from the chronic phase to blast transformation [14, 15].
The number of mutations can range from 1 to 5 or more
with or without abnormalities in the karyotype. Such
heterogeneity in MPN patients indicates a complex evo-
lutionary mechanism for the disease development. In
addition to directing the course of disease progression,
the combination of mutations also determines the re-
sponse to therapy. Therefore, identification of the gen-
etic lesions will be an essential feature of development of
effective therapeutic regimens.
These chronic clonal hematopoietic disorders can evolve
into acute myeloid leukemia (AML) as seen in 2 – 5 % of
PV or ET patients and 15–30 % of the PMF patients.
However, the molecular mechanisms that lead to trans-
formation are not well understood. A comparison of mu-
tations in MPNs with those in post-MPN AML shows
striking differences in the spectrum of gene sets involved
[12]. The genetic lesions in post-MPN AML predomin-
antly involved TP53, TET2, IDH1/2, ASXL1, SRSF2,
RUNX1, DNMT3a, CBL along with increase in cytogen-
etic aberrations that included recurrent deletions (4q, 5q,
6p, 7p, 7q) and uniparental disomy (19q, 22q, 11q) [16].
One of the most interesting features of post-MPN AML
was the loss of JAK2V617F mutation in the transformed
leukemic blasts [17]. It could be possible that JAK2 mu-
tant clones and leukemic blast clones arise independently
in the progenitor compartment or the JAK2 mutations are
lost by deletion. An analysis of a cohort of 16 PV pa-
tients with leukemic transformation showed that post-
PV MF and accelerated phase disease was associated
with JAK2 mutated AML while AML with WT JAK2
arose from chronic phase disease possibly as a conse-
quence of genotoxic therapy and damage to non JAK2
mutated HSCs [18]. Mutations in TP53 are rare in the
chronic phase but their frequency goes upto 45 % in
the leukemic blast phase [19]. These implicate genomic
instability and aberrant DNA damage response in the
evolution of MPN from a chronic disease to acute
leukemia. The precise sequence of mutations and their
role in the evolutionary process remain an active area
of investigation. Post-MPN AML shares spectra of mu-
tated genes and several cytogenetic features with de
novo AML. The increase in frequency of complex
karyotype and loss of JAK2 mutations in post-MPN
AML is associated with adverse prognosis. The loss of
JAK2 mutation is also going to make them resistant to
treatment with inhibitors specific for JAK2. Therefore,
molecules that target other survival and proliferation
regulatory pathways may have better therapeutic value.
PI3K pathway has generated much interest in AML
and is being investigated in several trials [4, 20]. How-
ever, the clinical response has been highly variable and
showed limited efficacy possibly due to poor patient
selection [21]. A more personalized approach and care-
ful patient selection on the basis of molecular lesions
may yield better results. Since MPNs involve clonal ex-
pansion of more mature compartments that rely on
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cytokine responsiveness, the mutations in the compo-
nents of cytokine signaling module and their effect on
the therapeutic outcomes will be discussed in more de-
tail in the next section.
Pathogenic molecular lesions in cytokine signaling
molecules leading to MPNs
JAK2 is a non-receptor tyrosine kinase that associates with
common β chain of IL-3 receptor, gp130 family receptors
and IFN-γ receptor and transduces signals downstream of
several cytokines [22]. The gain of function V617F muta-
tion leading to constitutive activation of signaling has been
detected in over 90 % of patients with PV and in upto 50 %
patients with ET and PMF. The rare JAK2V617F negative PV
patients carry mutations in the exon 12 of JAK2 that leads
to similar constitutive activation of the JAK2 and cytokine
independent signaling. Thus, aberrant signaling through
the JAK2 pathway accounts for almost all the cases of PV
(Fig. 1). However, it is not clear why PV, ET and MF have a
different phenotype despite carrying the same genetic mu-
tation. It has been proposed that these differences may be
attributable to mutation dose (copy number), differential
downstream signaling and presence of additional gen-
etic lesions [23]. In addition to mutations in JAK2, gain
of function mutation in thrombopoietin receptor (TPO-R),
myeloproliferative leukemia virus oncogene (MPL) at
W515 have been reported in ET and PMF. Around 5 % ET
and 10 % PMF patients negative for JAK2V617F, show pres-
ence of JAK2 exon 12 and MPL mutations (Fig. 1) that
effectively lead to constitutive activation of the same signal-
ing pathway [24, 25]. Subsequently somatic mutations in
calreticulin (CALR), a chaperone protein with known func-
tions in regulating protein folding and cellular calcium me-
tabolism, were detected in 67 % of the ET and 88 % of the
PMF patients that were negative for the JAK2 and MPL
mutations (Fig. 1) [26]. These mutations were clustered in
exon 9 and were absent in PV, AML, CML, MDS and
CMML patients or in healthy individuals suggesting that
these could serve as specific diagnostic markers for ET and
PMF. The mutations involve deletions (53 %), insertions
(32 %) and others leading to expression of the protein from
an alternative reading frame. The resulting mutant cal-
reticulin protein has a positively charged peptide at the
C terminal instead of the negatively charged in the
non-mutated protein. Ba/F3 cells expressing the mu-
tated protein acquire IL-3 independent proliferation
capacity along with increased phosphorylation of STAT5
though the mechanistic details remain unknown [26]. In
addition, loss of function mutations have been reported in
negative regulators of cytokine signaling such as adaptor
protein LNK (SH2B3) and CBL, a ubiquitin ligase that reg-
ulates the proteasomal degradation of some of the cytokine
receptors. These mutations will also effectively lead to un-
regulated constitutive activation of the cytokine signaling
pathways. It is interesting to note that mutations in JAK2,
MPL and CALR are mostly mutually exclusive and con-
verge on the activation of JAK/STAT signaling pathway.
However, in terms of outcome, the median survival time
for patients with ET (19.8 years) is longer than for PV
(13.5 years) and PMF patients have the shortest median
survival (5.9 years) [27]. Stratification of ET and PMF pa-
tients on the basis of presence of JAK2, MPL, CALR and
triple negative mutations showed no significant survival dif-
ferences in case of ET but mutational status affected the
survival of PMF patients. The triple negative PMF patients
had the shortest median survival time followed by JAK2
and MPL mutated, respectively. The longest survival times
were observed in CALR mutated patients [27]. Surprisingly,
Fig. 1 Schematic representation of the distribution of mutations in molecules associated with cytokine signaling in Ph-ve MPNs. The approximate
average values are shown
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this survival advantage in CALR mutated patients was re-
stricted to those carrying the deletion mutations in CALR
and in presence of insertion mutations the median survival
times were similar to JAK2 mutated patients though both
type of mutations result in change in charge and loss of ER
retention motif at the C-terminus of the protein [28]. Mu-
tations in chromatin regulators are frequent events in these
MPNs and patients carrying ASXL1, IDH, EZH2 or SRFS2
are at higher risk. Presence of ASXL1 mutation along with
CALR mutation was associated with reduction in median
survival times but the worst prognosis was observed in pa-
tients having mutation in ASXL1 and non-mutated CALR
[29]. These results further highlight the importance of de-
fining the different genetic lesions and consequent signaling
mechanisms for developing effective therapeutic regimen in
MPNs.
Mastocytosis, the newly added subgroup to Ph-ve
MPNs, involves clonal proliferation of mast cells and
their accumulation in different organs. Mature mast
cells express tyrosine kinase KIT, receptor for stem cell
factor and activating mutations in KIT are present in
mastocytosis and AML patients. Mutations at D816 are
present in majority of the adult systemic mastocytosis
(SM) patients and are also frequently associated with
pediatric cutaneous mastocytosis [30–32]. Additional
mutations in KIT, F522C, M541L, V560G, D820G and
E839K, have also been reported in mastocytosis pa-
tients. Similar to JAK2 mutations, the gain of function
mutations in KIT leads to constitutive activation of
downstream signaling pathways and cytokine independent
proliferation of the mutant cells. Tyrosine at position 719
within the cytoplasmic domain of mutant KIT plays an
important role in the growth factor independent activation
of STAT5 and PI3K/AKT/mTOR pathways [33]. Activation
of the PI3K pathway contributes to cell survival through
activation of Rho GTPase and Rho-associated coiled coil-
containing protein kinases (ROCK) and is essential for the
transformation by KIT D816V [34]. Some of the KIT muta-
tions are sensitive to inhibition by tyrosine kinase inhibitor,
Imatinib but D816V mutation present in a majority of sys-
temic mastocytosis patients is resistant to Imatinib [35, 36].
Dasatinib, a second-generation multi-kinase inhibitor, is
able to inhibit KIT mutations that are resistant to Imanitib
including D816V but it has met with little success in the
clinic [37, 38]. Thus, despite 2 decades of research to iden-
tify inhibitors of KIT, a cure for SM, an aggressive malig-
nancy is still not available. This has forced the researchers
to evaluate other downstream mediators of mutant KIT
signaling such as SHP2 phosphatase and p21 activated
kinase (PAK) as potential druggable targets [39–41].
A relatively rare, chronic neutrophilic leukemia (CNL)
characterized by elevated neutrophil counts is also in-
cluded as a myeloproliferative neoplasm in the WHO
2008 classification. A search for molecular basis of CNL
pathogenesis showed that deregulated signaling through
mutations in cytokine receptor might be pivotal in
Fig. 2 Schematic showing the PI3K pathway and the targets for therapy. Red stars indicate the molecules that are being specifically targeted by
small molecule inhibitors as single agents or in combination
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development of CNL also. Truncation and membrane
proximal mutations in colony-stimulating factor 3 recep-
tor (CSF3R), a transmembrane receptor, that lead to
cytokine independent proliferation appear to be specif-
ically associated with CNL [27–29]. CSF3R regulates
survival, proliferation and differentiation of granulo-
cytes in response to granulocyte colony stimulating factor
(G-CSF). T618I mutation in the membrane proximal region
with or without additional mutations that truncate the
cytoplasmic domain of CSF3R was observed in more than
80 % patients diagnosed with CNL as per the WHO criteria
[42–44]. Recapitulation of a fatal neutrophilic leukemia
phenotype upon transplantation of CSF3R T618I mutation
expressing hematopoietic cells further established a causal
role for CSF3R mutation in development of CNL [45]. Mu-
tations in CSF3R can therefore be a potential diagnostic
marker for CNL. The membrane proximal point mutations
vs truncation mutations in CSF3R may also have prognostic
and clinical relevance. The membrane proximal mutations
(T615A and T618I) in CSF3R were more potent in acquisi-
tion of cytokine independent growth and colony formation
as compared to the truncation mutations due to activation
of different signaling modules. The membrane proximal
mutations activate the JAK2/STAT3 signaling axis and are
sensitive to JAK inhibitor [42, 45] but insensitive to tyrosine
kinase inhibitor Dasatinib. While the truncation mutations
activate SRC family kinase, FGR/tyrosine kinase non-
receptor 2 signaling axis and are sensitive to dasatinib but
resistant to JAK inhibitors [42]. In addition presence of mu-
tations in SETBP1, encoding a nuclear protein that binds to
DNA replication associated SET oncogene, determines the
prognosis and response to therapy. Mutations clustered in
the D868 to D874 region of SETBP1 were found in 30 -
40 % of the CNL patients and was associated with shorter
life span. Interestingly, presence of SETBP1 mutation in
addition to CSF3R T618I conferred resistance to not only
conventional hydroxyurea therapy but also to JAK2 inhibi-
tor, ruxolitinib [46]. Thus, JAK2 inhibition may be effective
when only CSF3R T618I mutation is present but is likely to
be ineffective in presence of CSF3R truncation or additional
mutations such as SETBP1. Though it is not known which
pathways are activated by SETBP1 that contribute to the re-
sistance of double mutant cells. Since this data is based
on a study with a single patient, further studies in with
larger sample size will be required to establish the func-
tional role of SETBP1 mutations.
Chronic eosinophilic leukemia, not otherwise specified
(CEL-NOS) is another rare disease characterized by
clonal expansion of eosinophils that has been included
as a myeloproliferative neoplasm in the current classifi-
cation system by WHO. CEL-NOS is highly aggressive
with poor prognosis and high mortality. In a cohort of
10 CEL-NOS patients the median survival from the time
of diagnosis was only 22.2 months [47]. 50 % of the
patients had acute transformation with median time of
20 months, and died with median survival of 2 months
(range 1.0- 6.1) after acute transformation [47]. Since it
is a rare disease, the small sample size makes it difficult
to make conclusions about the molecular lesions that
contribute to the development of this disease. In a re-
cent study, Iurlo et al., [48] identified gain of function
M541L mutation in KIT in 4 out of 5 CEL-NOS patients
with non-mutated JAK2, BCR-ABL1, FIP1L1/PDGFRα
and TEL/PDGFRβ. These patients showed complete
hematological remission upon treatment with low dose
tyrosine kinase inhibitor (TKI) Imanitib, and were dis-
ease free upto 6 years after treatment with only one re-
lapse occurring after 4 years [48]. These results are in
stark contrast to poor prognosis and high mortality in
CEL-NOS patients with conventional treatments [47].
Therefore, though presence of KITM541L may not be a
molecular marker for CEL-NOS as it has also been ob-
served in pediatric mastocytosis [32] but identification
of the mutational status can make a significant differ-
ence in the treatment decisions and outcome of this
disease.
Inhibition of JAK signaling in treatment of MPN
Aberrant regulation of cytokine dependent signaling path-
ways appears to be the unifying molecular feature in all the
Ph-ve MPNs. Acquisition of the mutations discussed above
lead to enhanced cytokine sensitivity and clonal prolif-
eration of lineage committed cells. In the absence of
knowledge of the molecular mechanisms, the treatment
options were limited to phlebotomy, hydroxyurea, in-
terferons, and immunomodulatory agents to provide
symptomatic relief to the patients [6]. JAK2 has been
the target of choice since JAK2V617F was the first and is
the most frequent mutation associated with classical
Ph- ve MPNs. Ruxolitinib (INC424/ INCB018424/
Jakafi), a specific inhibitor of JAK kinases, was the first
inhibitor to be approved by FDA for the treatment of
high and intermediate risk MF and PV. There was a
marked and durable decrease in spleen size and disease
associated pathologies upon treatment with Ruxolitinib
as compared to the standard available therapy leading
to improvements in the quality of life [49, 50]. Success
with Ruxolitinib raised the hopes but it was not curative.
Additionally, treatment with Ruxolitinib was associated
with thrombocytopenia and anemia in a significant number
of MF patients undergoing the phase III trial. The beneficial
effects of Ruxolitinib though encouraging, turned out to be
limited in scope. [51, 52]. Partial success with Ruxolitinib
has spurred the search for other JAK kinase inhibitors with
improved efficacy and reduced toxicity. Pre clinical and
clinical data with Fedratinib (TG101348/SAR302503), the
second JAK kinase inhibitor to have entered phase III clin-
ical trial, were promising but further development had to
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be discontinued following Wernicke’s encephalopathy in
these patients [53]. Similarly, clinical trials had to be
terminated and further development discontinued due
to severe pleiotropic neurological adverse effects in pa-
tients treated with JAK inhibitors, AZD1480 (clinical
trial NCT01219543) or XL019 [54, 55]. None of the
JAK2 inhibitors are specific to the mutated protein and
in addition to JAK2 they can also inhibit JAK1 activity
thereby leading to non-specific effects and toxicity.
While new molecules continue to be evaluated for tar-
geting the JAK/STAT pathway, a combinatorial ap-
proach is also being tested to reduce the toxicity and
increase the efficacy [56, 57]. Some of these combinations
are designed to target the side effects of Ruxolitinib therapy
such as anemia, MPN associated fibrosis, or the histone
acetylation and DNA methylation which is frequently
deregulated by the mutations in the regulators of the epige-
nome (Table 1). However, not all MPNs have mutations in
JAK2 or activate the JAK/STAT signaling and are therefore,
not likely to respond to JAK2 inhibition therapy. Some of
the mutations, such as those in c-KIT can directly activate
PI3K and other signaling pathways. In addition, very little is
known about the mechanisms that contribute to enhanced
proliferation and cytokine responsiveness in the triple nega-
tive group in PMF patients. PI3K/AKT/mTOR is a central
signaling module and several other pathways converge on it
to regulate cell survival and proliferation. It is also constitu-
tively activated in MPNs and targeting it either alone or in
combination has yielded encouraging results. Since the
PI3K/AKT/mTOR signaling axis is deregulated in various
other cancers, significant efforts have been channeled to
identify small molecular inhibitors of this pathway. These
molecules are already in various stages of pre clinical and
clinical evaluations. Therefore, these inhibitors of PI3K
pathway can become rapidly available to MPN patients.
Phosphatidylinositol 3 Kinase pathway in MPN
There are three classes of PI3K and the focus will be on
class IA since it plays a central role in normal develop-
ment as well as in the pathogenesis of different cancers.
Phosphatidylinositol 3 kinase pathway is activated at the
cell surface and integrates signals from cytokines, growth
factors and environmental cues and transmits them
through AKT and mTOR to effector molecules that con-
trol protein synthesis, growth, survival and proliferation
[58, 59]. The active PI3K enzyme consists of a heterodi-
mer of a catalytic subunit and a regulatory subunit. The
catalytic subunits p110α, p110β, and p110δ are encoded
by Pik3ca, Pik3cb, and Pik3cd, respectively while Pik3r1,
Pik3r2, and Pik3r3 encode the class IA PI3K regulatory
subunits p85α, p85β and p55γ, respectively. Alternate
codon usage from Pi3r1 generates two additional
Table 1 Ongoing clinical evaluations of ruxolitinib in combination with other compounds for treatment of MPNs
Compounds Target/mechanism National Clinical Trial
Identifier
Phase Condition Status
Decitabine Anti-metabolite chemotherapeutic,
DNA demethylation
NCT02076191 I/II Accelerated or
blast phase MPN
Recruiting
Azacitidine (Vidaza) Chemical analogue of nucleoside
cytidine, antimetabloite chemotherapeutic
NCT01787487 III MF, MDS/MPN Recruiting
NCT02257138 I/II AML, post
MPN-AML
Active, not recruiting
Danazol Synthetic steroid derived from ethisterone,
used in endometriosis treatment
NCT01732445 II Anemia in PMF,
post ET/ PV MF
Recruitment suspended
for interim data to mature
Pracinostat (SB939) Hydroxamic acid based histone deacetylatase
inhibitor of class 1/2/4 HDACs
NCT02267278 II MF Active, not recruiting
Panobinostat (LBH589) Hydroxamic acid based non selective HDAC
inhibitor
NCT01693601 I/II MF Recruiting
NCT01433445 I PMF, post
ET/ PV MF
Active, not recruiting
Pomalidomide
(CC-4047-MM-002)
Derivative of thalidomide, inhibits angiogenesis,
immunomodulator
NCT01644110 I/II PMF, post
ET/PV MF
Recruiting
Lenalidomide Anti-angiogenic, immunomodulator NCT01375140 II MF Active, not recruiting
Simtuzumab
(GS-6624)
Humanized monoclonal antibody, binds to
LOXL2 and inhibits fibrosis
NCT01369498 II PMF, post
ET/PV MF
Completed
PRM-151 Recombinant pentraxin-2 protein (acute
immunological responses) inhibits fibrosis
NCT01981850 II PMF, post
ET/PV MF
Recruiting
BKM120 PI3K inhibitor NCT01730248 I PMF, post
ET/PV MF
Recruiting
LDE225 Investigational inhibitor of Smoothened (SMO),
a regulator of hedgehog signaling pathway
NCT01787552 Ib/II PMF, ET, MPD Recruiting
The clinical trials registry and database [53] was searched for ongoing clinical trials of Ruxolitinib (Jakafi/ INCB18424) in combination with other therapeutics and
studies enlisting MPN patients were tabulated. The information presented is current as of 24th January 2015
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regulatory units, p55α and p50α. There is no specificity
with regard to association between regulatory and cata-
lytic subunits. Any regulatory subunit can associate with
any of the catalytic subunits present. Cell type specificity
in PI3K activity is achieved through cell lineage specific
expression of the different isoforms. Class 1 PI3K utilize
the lipid substrate, phosphatidylionsitol-45, biphsophate
(PIP2) and catalyze the phosphorylation at 3-position in
the ring to generate the active second messenger, phos-
phatidylinositol3,4,5- triphoshpate (PIP3). In unstimu-
lated cells, the regulatory subunit binds to the catalytic
subunit and inhibits the catalytic activity. Upon stimula-
tion, the regulatory subunit is recruited to the phospho-
tyrosine proteins present at the cell membrane and the
catalytic unit catalyzes the formation of PIP3 that in turn
acts as a tethering moiety for AKT. Upon recruitment to
the membrane, AKT is phosphorylated and in turn acti-
vates mammalian target of rapamycin (mTOR), a serine
threonine kinase and other proteins involved in cell sur-
vival and proliferation (Fig. 2). The signaling is attenu-
ated by the lipid phosphatases, PTEN and SHIP that
dephosphorylate and convert PIP3 back to PIP2 and the
inhibitory feedback circuitry [60, 61].
Hyperactivation of the PI3K signaling module has been
observed in a large number of solid cancers and
hematological malignancies. This may either be due to
oncogenic activation of receptor tyrosine kinases and/or
also due to increased expression, copy number gain, am-
plifications or mutations in Pik3ca, Pik3r1, AKT, TSC1/2
and PTEN [62, 63]. In MPN patient bone marrow biopsy
samples with JAK2V617F or KITD816V mutation, increase
in phosphorylation of AKT indicates constitutive activa-
tion of the PI3K pathway [64]. PI3K regulatory subunits
p85α and p85β appear to have different roles in trans-
formation of myeloid cells by mutant KIT. While genetic
deletion of p85α abrogated the cytokine independent
growth and leukemogenic activity of KITD814V, deletion
of p85β had no effect on the growth factor independent
proliferation [65, 66]. Similarly, consistent with the se-
lective expression of the p110δ catalytic subunit in the
leucocytes, specific inactivation of p110δ but not that of
p110α inhibited the hypersensitivity to GM-CSF due to
presence of activating mutation in Shp2 phosphatase
and subsequent activation of the PI3K signaling module
[67]. In addition to contributing to pathogenesis of neo-
plasms, constitutive activation of PI3K pathway also con-
tributes to resistance to tyrosine kinase inhibitors (TKI).
This development of resistance is not due induced muta-
tions in BCR-ABL1 [68]. The epigenetic silencing of
PTEN in response to therapy and consequent activation
of the PI3K/AKT along with other pro-survival pathways
possibly mediates drug resistance [69]. Given the crucial
role of PI3K signaling module there is intense interest in
finding specific drugs and more than 40 molecules by
different pharmaceutical companies are in different
stages of clinical evaluations (Table 2).
Targeting the PI3K Pathway
The PI3K signaling module has emerged as one of the most
attractive target in cancer therapeutics due to its central
role in integrating signals from different receptor kinases to
regulate cell survival and proliferation. Significant efforts
have been devoted to identify small molecule inhibitors that
can block the PI3K pathway at one or more of the signaling
nodes (Table 2). Accordingly, they can be broadly classified
as inhibitors of (1) PI3K (2) AKT and (3) mTOR (Fig. 2).
Additionally some inhibitors can target the PI3K pathway
at more than one node and they are grouped as dual-
specificity inhibitors. These molecules are in various stages
of pre-clinical and clinical evaluation either as single agents
or in combination with other therapeutics in advanced solid
tumors and hematological malignancies. Though some
of these molecules hold promise, so far the success has
been limited. Clinical trials with GSK1059615, a PI3K
α inhibitor (NCT00695448), GSK690693, inhibitor of AKT
(NCT00493818) and AZD2014, mTORC1/2 inhibitor
(NCT00493818) had to be terminated due to limited effi-
cacy or drug related toxicities [70]. While further develop-
ment of GSK1059615 and GSK690693 has been stopped,
AZD2014 is being evaluated in several clinical trials in
combination with other agents (Table 2). Some of the PI3K
pathway inhibitors have also been evaluated in models of
MPN and have entered the clinic as discussed below. As
the safety and efficacy of these small molecules is estab-
lished in the early clinical trials with solid cancers and
lymphomas, clinicians will have more options to choose
from while designing the therapeutic strategies for MPN
patients based on the mutational status and molecular
markers. Interestingly, majority of the small molecule
inhibitors of the PI3K signaling module have oral bio-
availability (Table 2) which is better suited for the man-
agement of chronic diseases like MPN and ensuring
patient compliance.
Inhibitors of PI3K
The inhibitors of the class IA PI3K can be further subdi-
vided into pan PI3K inhibitors and isoform specific inhibi-
tors. The first generation pan Class I PI3K inhibitors,
Wortmanin and LY294002 had potent activity in vitro
model systems but they did not make it to the clinic due to
severe toxicities observed in vivo. PX-866, a synthetic de-
rivative of wortmannin and irreversible pan PI3K inhibitor,
was found to be safe and well tolerated in patients who had
already undergone 3 or more therapies for advanced solid
cancers [71]. Interestingly, PX-866 also inhibited TGF-α/
EGFR induced lung fibrosis in preclinical models when
used as a single agent or in combination with MEK inhibi-
tor [72, 73]. These results raise the hope that inhibition of
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Table 2 Inhibitors of the PI3K/AKT/mTOR pathway in the clinic
Compound Target specificity Availability Mechanism Phase Cancer
Afuresertib (GSK2110183) AKT 1/2/3 Oral ATP competitive I, II MM, CLL, Solid cancers
BAY1125976 AKT 1/2 Oral Allosteric, Non-ATP
competitive
I Advanced solid tumors
RX-0201 (Archexin) AKT 1 IV Antisense
oligodeoxymucleotide
I/II, II Pancreatic, Renal
ARQ 092 Pan AKT, selectivity for AKT1 Oral ATP competitive I Solid tumors, recurrent
Lymphoma
GDC-0068 AKT 1/2/3 Oral Non-ATP competitive I, II Solid cancers
Uprosertib (GSK2141795) AKT 1/2/3 Oral ATP competitive II Solid cancers, AML, MM
MK2206 Pan AKT, selectivity for AKT1 Oral Allosteric, Non-ATP
competitive
II Solid tumors, lymphoma
SR13668 AKT Oral Blocks AKT phosphorylation I Healthy volunteers
(completed)
LY2780301 AKT/p70S6K Oral ATP competitive I/II Advanced solid tumors,
non-hogdkin’s lymphoma
AZD5363 AKT, 1/2/3 P70S6K/PKA Oral ATP competitive I/II Solid cancers
ONC201 (TIC10) AKT/ERK Oral Indirect I/II Advanced solid tumors
BKM120 (buparlisib) PI3K Oral ATP competitive II, III Advanced cancers
ZSTK474 PI3K Oral S-triazine derivative,
ATP-competitive
I/II Advanced solid tumors
Copanlisib (BAY 80–6946) PI3K IV Imidazolinoquinazoline
derivative
I. II Advanced solid tumors, NHL
PX-866 PI3K Oral Wortmannin analogue,
irreversibly binds catalytic
site
I/II Solid tumors
XL147 (SAR245408) PI3K (MEK/ERK) Oral ATP competitive I Advanced solid tumors
BYL719 PI3K alpha Oral 2-aminothiazole derivative I/II Advanced solid tumors
INK1117 (MLN1117) PI3K alpha Oral I Metastatic solid tumors
AZD8186 PI3K beta Oral I CRPC, sqNSCLC, TNBC, PTEN
deficient advanced cancers
GSK2636771 PI3K beta Oral substituted benzimidazole I/II CRPC, PTEN deficient solid
tumors
Idelalisib (Zydelig, CAL-101,
GS-1101)
PI3K delta Oral Quinazoline class III NHL, FDA approved for
relapsed CLL, SLL, FL
INCB040093 PI3K delta Oral I B cell malignancies
INCB050465 PI3K delta I Relaposed/ refractory B cell
malignancies
BAY1082439 PI3K alpha/beta Oral I Advanced solid tumors
GDC-0941 bismesylate PI3K alpha/delta Oral ATP competitive I/II TNBC, NSCLC
AZD8835 PI3K alpha/delta Oral I Advanced solid tumors
GS-9820 (CAL-120) PI3K beta/delta Oral Ib Lymphoid malignancies
RP6530 PI3K gamma/delta Oral I Hematological malignancies
IPI-145 PI3K gamma/delta Oral ATP competitive I, III Hematological malignancies,
follicular lymphoma
DCBCI0901 PI3K/mTORC1/2 IV I Advanced solid tumors
P7170 PI3K/mTOR/DNA-PK/ALK-1 Oral I Advanced refractory tumors
VS-5584 PI3K/mTOR Oral I Non hematological cancers,
metastatic cancers, Lymphoma
DS-7423 PI3K/mTOR Oral I Solid tumors, completed
PF-05212384 PI3K/mTOR IV I Advanced solid tumors
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the PI3K pathway by PX-866 may be effective in managing
PMF and post ET/PV-MF. BKM120 is another promising
pan class I PI3K inhibitor that has reached phase III in clin-
ical trials with advanced solid tumors (Table 2). In addition
to inhibiting the tumor cell growth, BKM120 also blocked
the protective signals from the microenvironment in pre-
clinical models of T-ALL and CLL [74, 75]. BKM120 is cur-
rently being investigated in the clinic in combination with
ruxolitinib for treatment of MF (Table 1). However, it re-
mains to be seen if any of these PI3K inhibitors will be suc-
cessfully applied for the management of MPNs.
While promising leads have been obtained with pan class
I PI3K inhibitors, efforts have also been directed to develop
isoform specific inhibitors to limit systemic toxicities
(Table 2). While p110α and β isoforms have a more ubiqui-
tous tissue distribution, p110δ has a more restricted expres-
sion in the hematopoietic system. Therefore, inhibitors
directed at p110δ catalytic subunit are being preferentially
evaluated in hematological malignancies (Table 2). Idelalisib
(also known as Zydelig, CAL-101, GS-1101) became the
first in this class of inhibitors to get FDA approval for use
in relapsed and refractory CLL, follicular B-cell non-
Hodgkin lymphoma and relapsed small lymphocytic
lymphoma. In the clinic, Idelalisib is efficacious as a single
agent as well as in combination with rituximab in CLL pa-
tients who had treatment refractory disease or were unsuit-
able for standard chemotherapy [76, 77]. In pre-clinical
evaluations, a PI3K α/δ inhibitor, GDC-0941 inhibited the
proliferation driven by mutant KIT in 32D cells [33] while
Idelalisib and another PI3K δ specific inhibitor, GS-9820
(Table 2) inhibited the GM-CSF induced proliferation of
bone marrow cells expressing the constitutively active Shp2
phosphatase mutant with concomitant reduction in AKT
phosphorylation [67]. These results indicate that isoform
specific inhibition of p110 catalytic subunit may also benefit
MPN patients. Idelalisib is particularly interesting as in
addition to induction of apoptosis in the leukemic cells, it
antagonizes the protective effect of bone marrow stroma
on CLL cells by blocking the expression of BCR induced
lymphocyte cytosolic protein 1 (LCP1). It also interferes
with cytoskeleton rearrangement and migration thereby
leading to CLL cell de-adhesion and apoptosis [78, 79].
IPI-145, inhibitor of p110 δ and γ isoforms has also
been found to be safe and efficacious in phase I trial.
Notably, IPI-145 also antagonized extracellular survival
signals and sensitized ibrutinib resistant cells with BTKC481S
mutation [80]. IPI-145 also exerts anti-inflammatory activ-
ity through modulation of chemokine secretion, neutrophil
Table 2 Inhibitors of the PI3K/AKT/mTOR pathway in the clinic (Continued)
BEZ235 PI3K/mTOR Oral Imidazo (4,5) quinoline
derivative,
ATP competitive
I/II Advanced solid tumors
XL765 (SAR245409) PI3K/mTOR Oral I/II Advanced solid tumors
BGT226 PI3K/mTOR Oral I/II Advanced solid cancers,
completed
GDC-0980 PI3K/mTOR I/II NHL, EC, Solid tumors
GSK2126458 PI3K/mTOR Oral Pyridylsulfonamide
derivative
I Refractory solid tumors
PWT33597 mesylate
(VCD-597)
PI3K alpha/mTOR Oral Derived from pan-Class I
PI3-kinase ATP competitive
inhibitor ZSTK474
I Advanced malignancies
MLN0128 (INK128) TORC1/2 Oral ATP competitive I,II Advanced solid and
hematological malignancies
OSI-027 TORC1/2 Oral 4,5,7-trisubstituted imidazo
[5,1-f] triazine
I Solid tumor, lymphoma
AZD8055 TORC1/2 Oral ATP competitive, inhibits
kinase activity
I Advanced cancers
AZD2014 TORC1/2 Oral ATP competitive I/II Advanced solid cancers
CC-223 TORC1/2 Oral ATP competitive I/II MM, DLBCL, NHL, solid
cancers
ME-344 (NV-128 mTOR IV Isoflavone derivative I Solid tumors
ABTL0812 TORC1/2, DHFR Oral Lipid analogue I Advanced tumors
CUDC-907 PI3K/HDAC Oral I Advanced solid tumors, MM
The drug dictionary maintained by National Cancer Institute (http://www.cancer.gov/publications/dictionaries/cancer-drug) was mined for inhibitors of the PI3K
signaling module and information on their status in clinical trials was obtained from the clinical trial registry database [53]. Abbreviations: MM- multiple myeloma,
CLL – chronic lymphocytic leukemia, AML – acute myeloid leukemia, NHL – Non Hodgkin’s lymphoma, TNBC – triple negative breast cancer, CRPC – castration
resistant prostate cancer, NSCLC - Non-small cell lung carcinoma, SLL - small lymphocytic lymphoma, FL- follicular B-cell non-Hodgkin lymphoma, DLBCL - Diffuse large
B-cell lymphoma, IV - intravenous
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migration and activation of basophils [81]. It is interesting
to note that some of these isoform specific inhibitors are
not only toxic to the transformed cells but can also counter
the protective effects of the microenvironment and reduce
inflammation, two of the critical contributors to leukemic
transformation and resistance to therapeutics in vivo. Taken
together these results provide a strong rationale for evalu-
ation of PI3K inhibitors in MPN models but the success is
likely to be dependent upon patient selection on the basis
of genetic lesions.
Inhibitors of mTOR
Mammalian target of rapamycin (mTOR), a serine threo-
nine kinase with homology to the PI3K, is present as part
of two different complexes – mTORC1 and mTORC2
(Fig. 2). mTORC1 includes raptor, mLST8, PRAS40 and
DEPTOR and is mainly involved in regulating cell growth
and protein synthesis through its downstream effectors,
S6 kinase and 4E-Binding Protein 1 (4EBP1). On the other
hand, mTORC2 complex includes rictor, mLST8, DEP-
TOR, mSin1 and protor. mTORC2 plays a role in survival
signaling through phosphorylation of AKTS473 and serum
and glucocorticoid-inducible kinase (SGK). Rapamycin
was the first allosteric inhibitor of the mTOR complex
and has led to development of next generation inhibitors
referred to as rapalogs that include everolimus and temsir-
olimus [82]. These primarily inhibit mTORC1 by interact-
ing with FK binding protein 12 (FKB12) and have little or
no effect on mTORC2. Differential expression of
mTORC1 and mTORC2 in immature and neoplastic mast
cells versus the terminally differentiated mast cells may
provide a therapeutic window for selectively targeting the
mTORC2 [83]. It may be possible to inhibit the prolifera-
tion of only the neoplastic cells while leaving the function-
ality of terminally differentiated mast cells intact.
Rapamycin was reported to selectively inhibit phosphoryl-
ation of 4E-BP1 and induce apoptosis in mast cells with
D814V mutation [84]. These results suggested that target-
ing mTOR might be successful in treatment of systemic
mastocytosis. However, no clinical benefit was observed in
a phase II clinical trail with everolimus (RAD001) in a co-
hort of 10 patients with either indolent or aggressive sys-
tematic mastocytosis [85]. However it is worth noting that
6 of these 10 patients had been treated with other agents
previously and had possibly activated compensatory
mechanisms that might have made them resistant to
therapy. More promising results were observed in an-
other phase I/ II clinical trial with everolimus in a co-
hort of 39 patients with primary and post-PV/post-ET
MF even though in this study too over 80 % of the pa-
tients had been unresponsive to previous treatment
with at least one conventional therapeutic regimen of
either cytotoxic drugs, interferon therapy, erythropoi-
esis stimulation, or immunomodulatory agents [86].
44 % response rate was observed for splenomegaly
while complete resolution of constitutional symptoms
and pruritus was reported in 69 % and 80 % of the pa-
tients, respectively with modest hematological and
non-hematological toxicities. Patient response showed
strong correlation with reduction in p70S6K phosphor-
ylation in responders while no significant differences
were observed in the plasma proteins or inflammatory
cytokines and circulating CD34+ cells [86]. Interest-
ingly, the response to Everolimus was independent of
the mutation status of JAK2 or MPL [86]. These results
demonstrate that inhibition of mTOR by rapalogs can
provide symptomatic relief leading to improvement in
quality of life.
In addition to the rapalogs, ATP competitive inhibitors of
mTOR complex have been developed. Since these inhibi-
tors inihbit both mTORC complexes, they target the up-
stream mTORC2 complex that activates AKT as well as its
downstream substrate mTORC1 complex thereby effect-
ively acting on the pathway at 3 nodes (Fig. 2). The growth
factor independent proliferation of 32D cells with mutant
KIT was susceptible to inhibition by the mTORC1/2 inhibi-
tor, AZD8055 [33]. Similarly, in another recent pre-clinical
study, PP242, a ATP competitive inhibitor of mTOR was
shown to inhibit cell cycle progression and colony for-
mation as effectively as RAD001 (everolimus) in
erythropoietin-independent cell lines and progenitor
cells from PMF and PV patients with JAK2V617F muta-
tion. It is worth noting that PP242 was also effective
against RAD001 resistant JAK2V617F human cell lines
and had pro-apoptotic activity in contrast to the cyto-
static activity of RAD001 [87]. These differences can be
attributed to the ability of PP242 to inhibit both
TORC1/2 while RAD001 inhibits only TORC1. 4E-BP1
has rapamycin resistant phosphorylation at Thr37/46
that is possibly mediated through serine/threonine kin-
ase Pim2 and maintains cap dependent translation [88].
Therefore, catalytic site inhibitors of mTOR are more
likely to be successful as therapeutic drugs. However,
while the inhibitors effectively block mTOR activity,
they also block the feedback inhibition leading to in-
crease in AKT Thr308 phosphorylation by PI3K/PDK1
hyper activation [89]. Taken together the data from
pre-clinical and clinical trials supports a pivotal role for
mTOR in pathogenesis of MPNs. Further, taking into
consideration the moderate success observed in pa-
tients that had already developed resistance, inclusion
of mTOR inhibitors in the first line therapy may prove
to be more beneficial.
Inhibitors of AKT/PKB
AKT, a serine threonine kinase with three isoforms
encoded by different genes, is another potential target in
the PI3K signaling pathway. AKT is recruited to the cell
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membrane in response to the lipid second messenger,
PIP3 through its pleckstrin homology domain where it is
phosphorylated by phosphoinositide-dependent protein
kinase 1 (PDK1) and mTORC2 at Th308 and S473 which
in turn regulates TSC2/ mTORC1, GSK3β, MDM2 and
Bcl2 family proteins. Inhibitors of the AKT kinases in
the clinic include ATP-competitive molecules, allosteric
inhibitors, lipid mimetics and antisense nucleotide
(Table 2). Some of these inhibitors in the pre clinical
studies using in vitro and mouse models of MPN have
shown promise. An allosteric, non-ATP competitive and
orally bioavailable AKT inhibitor, MK-2206, has been
established as safe and tolerable in Phase I clinical trials
in patients with solid tumors. MK-2206 inhibited AKT
phosphorylation in MPN cell lines with JAK2V617F muta-
tion as well as in CD34+ peripheral blood cells. This was
associated with reduction in phosphorylation of pro-
apoptotic protein, BAD and induction of cell death [90].
MK-2206 was also efficacious in a mouse model of mye-
lofibrosis induced by transplanting MPLW515L expressing
cells. Treatment with MK-2206 was associated with re-
duction in CD41+ cells and AKT phosphorylation and in
the bone marrow, significant reduction in peripheral
WBC and megakaryocytes in liver, spleen and bone mar-
row with no overt hematological toxicity [90]. Interestingly
activation of AKT in AML patients contributes to acquisi-
tion of resistance to Gemtuzumab ozogamicin(GO), an
anti-CD33 antibody conjugated to a calicheamicin-γ(1) de-
rivative and MK-2206 can sensitize these cells in vitro [91].
These results provide further evidence of activation of the
PI3K pathway in MPNs with mutations in cytokine/JAK2
pathway and are encouraging for specific targeting of AKT
during the chronic and leukemic phases. However, the ben-
efits in the clinic are yet to be realized.
Two other inhibitors of AKT activation, UCN-01, a
staurosproine derivative that blocks PDK1 mediated
phosphorylation of AKT [92] and Perifosine an orally
available alkylphospholipid that prevents recruitment of
AKT to membrane for activation [93], were evaluated in
combination in a phase I trial in AML and MDS pa-
tients. Though the combination was well tolerated and
phosphorylation of ribosomal protein S6 was reduced in
the blast samples, the combination was not effective in
inhibiting AKT phosphorylation [94]. However it is
worth nothing that a demonstrable increase in baseline
phosphorylation of the AKT target was not present in all
the patients. Furthermore, validity of using S6 phosphor-
ylation as biomarker for AKT/mTORC1 inhibition is
questionable as phosphorylation of 4E-BP1, another
mTORC1 target does not correlate with S6 phosphoryl-
ation [88]. These results highlight the need for sensitive
and predictive biomarkers for assessing the effectiveness
of the inhibitors. It is also possible that all patients may
not have constitutive activation of AKT and therefore,
may not be good candidates for therapeutic regimens
based on inhibition of AKT. A more personalized ap-
proach based on molecular characteristics of individual
patients is more likely to be successful. Additionally, as
discussed below, it might be more prudent to combine
inhibitors that target different pathways rather than tar-
geting the same molecule.
Inhibitors with dual specificity
Development of dual specificity inhibitors is an alterna-
tive approach to blocking the activation of PI3K/AKT/
mTOR pathway at multiple levels rather than a single
node at a time. These take advantage of the high degree
of homology in the kinase domains of PI3K and mTOR.
The dual specificity inhibitors bind to the active site of
both, PI3K and mTOR. BEZ235, a dual specificity inhibi-
tor of the PI3K/ mTOR pathway developed by Novartis
inhibited the proliferation of growth factor independent,
clonal proerythroblastic murine cells as well as human
mast cell line carrying the D816V mutation with cells
being arrested in G1 phase [95, 96]. It was interesting to
note that despite increasing the drug concentration,
complete inhibition could not be achieved. Interestingly,
there was no increase in cell death at growth inhibitory
concentrations. Cell proliferation and survival may be
regulated by parallel pathways and it would be possible
to get synergism by a combination that targets these two
pathways. Consistent with this notion, strong synergy
and complete inhibition of proliferation with induction
of cell death was observed when BEZ235 was combined
with UO126 that abrogated MEK/ERK signaling or Oba-
toclax that blocked pro-survival signaling by the Bcl2
family proteins [96]. In contrast, in cells expressing
JAK2V617F, BCR-ABL1 or BRAFV600K, treatment with
BEZ235 was able to overcome the resistance to inhibi-
tors conferred by mutation in G protein β 1 subunit and
induced apoptosis [97, 98]. In addition to being effective
against cell lines carrying the JAK2 mutation and pri-
mary MF cells, BEZ235 also demonstrated synergism
with JAK2 inhibitors, TG101209 and SAR302503 [97].
XL147, a pan PI3K inhibitor is in phase I trial in patients
with advanced solid cancers. It was interesting to note
that as expected, XL147 inhibited phosphorylation of the
downstream targets of PI3K pathway (AKT, PRAS40,
4EBP1, and S6) and in addition also inhibited the MEK/
ERK pathway [99]. Compensatory activation of the
MEK/ERK pathway plays an important role in develop-
ment of resistance to PI3K inhibitors. Therefore, co-
inhibition of both the pathways by the same molecule
would eliminate signaling by both PI3K pathway and the
drug resistance inducing MEK/ERK pathway. In addition
to the dual specificity inhibitors that target PI3K and
mTOR a unique dual specificity inhibitor, CUDC-907
has entered the clinic (Table 2) [100]. CUDC-907
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combines the inhibitory activity for class I and IIb his-
tone deacetylase (HDAC) enzymes with inhibition of
PI3K α, β and δ isoforms [101]. Acetylation of proteins
and their deacetylation by HDACs regulate the activity
of several cellular proteins in addition to that of the his-
tones. One such protein is HSP90, a chaperone protein.
Increase in acetylation in presence of HDACi leads to
increase in proteasomal degradation of mutant oncopro-
teins such as JAK2, KIT and AKT [102]. The loss of mu-
tated oncoproteins will therefore, lead to elimination of
the pathogenic clones. Thus CUDC-907 simultaneously
targets both the driving oncoprotein and the aberrant
PI3K signaling. Since many of the MPNs also carry mu-
tations in proteins that deregulate the epigenome, com-
bining the epigenetic modifying activity with inhibition
of signaling holds promise. The complete data is not yet
available but the early results indicate that CUDC also
targets the microenvironment due to its anti-angiogenic
activity [101]. Earlier the emphasis had been on the spe-
cificity of the chemical inhibitors. However, the current
trends and results from the clinic show emergence of
drug resistance due to hyper activation of compensatory
pathways when one single pathway is targeted. With the
emergence of the concept of ‘signaling networks’ rather
than ‘linear pathways’, molecules that target different
nodes in the network would possibly be more effective
in shutting down a ‘pathway’ rather than targeting a sin-
gle node.
Combination therapy
Constitutional toxicities, sub-optimal efficacy at lower
doses and frequent development of resistance due to ac-
tivation of compensatory survival pathways have limited
the success with single drug based therapies. In addition
the complex molecular heterogeneity usually found in
MPNs and a very variable evolutionary trajectory in pa-
tients makes it a challenge to target with a single drug.
Though MPL and JAK2 mutations would activate the
same downstream signaling pathway in PMF patients
but have different prognosis in terms of median survival
and leukemic transformation [29]. This is likely to be in-
fluenced by other mutations and cytogenetic abnormal-
ities. Over the course of the disease distinct clones may
evolve with different combinations of mutations. Coex-
istence of subclones with different combinations of gen-
etic aberrations and drug sensitivities makes it harder to
target with a single molecule. Patients with CALR muta-
tion may respond to JAK2 inhibitor but when it is
present in combination with mutation in SETBP, the
cells are resistant to the same treatment [46]. More such
studies are needed to clarify how additional mutations
contribute to the sensitivity of the cells to these drugs
but it is reasonably clear that no single drug is likely to
be successful for any of these MPNs. The treatment
strategies will have to be more personalized to account
the combination of mutations and presence of sub
clones. Co-targeting different pathways either sequen-
tially or concomitantly is likely to be more effective
strategy in such a scenario. In order to identify the path-
ways that work synergistically with the constitutionally
active JAK pathway, Choong et al. [103] used a panel of
small molecule inhibitors directed against CDK, MEK/
ERK, JNK, p38 MAPK, Raf, PI3K and mTOR in combin-
ation with JAK2 inhibitor ruxolitinib. They found signifi-
cant synergism with mTOR and MEK/ERK inhibitors
while inhibitors of other signaling pathways had little or
no effect. Interestingly, most potent synergistic effect
was observed with pan PI3K inhibitors (ZSTK474 and
GDC0941) and PI3K/mTOR dual inhibitor NVP-
BEZ235. When used in combination they inhibited
phosphorylation of STAT3/5 and p70S6 Kinase/S6 ribo-
somal protein, the targets of the JAK and PI3K pathway
[103]. BEZ235 also demonstrated synergism with other
JAK2 inhibitors, TG101209 and SAR302503 [97] as well
as UO126, inhibitor of MEK/ERK signaling and Obato-
clax, inhibitor of Bcl2 family proteins [96]. While the
combination of PI3K inhibitor with JAK2 inhibitor did
not prolong the survival of mice transplanted with
JAK2V617F cells, there was 70 % and 60 % reduction in
spleen weight as compared to the vehicle treated con-
trols and single drug treated groups, respectively [103].
A relief from the symptoms of the disease can improve
the quality of life. Similar synergistic effects were ob-
served using RAD001, allosteric or PP242, ATP competi-
tive inhibitors of mTOR in combination with JAK2
inhibitors ruxolitinib or AZD1480 in proliferation and
clonogenic assays using mouse and human cells carrying
JAK2V617F mutation [87]. Interestingly, INCB040093 an-
other p110 δ inhibitor in phase I trial (Table 2), was inef-
fective as a single agent in DLBCL cells with activated
JAK/STAT signaling pathway but the cells could be sen-
sitized by a combination treatment with JAK1 inhibitor
[104]. Upon combining PI3K inhibitor with JAK inhibi-
tor there was little effect on AKT phosphorylation [103]
suggesting that alternative pathways can activate AKT
and their concomitant suppression may enhance the
therapeutic potential. Consistent with this notion, highly
synergistic inhibition of proliferation was observed when
AKT inhibitor, MK-2206 was combined with ruxolitinib
in human cell line with JAK2V617F mutation [90]. In
addition to targeting the proliferating myeloid clones, a
combination of PI3K inhibitor PX-866 with MEK inhibi-
tor also attenuated lung fibrosis in preclinical models
[73] and may benefit MF patients. These results look
promising and provide a strong rationale for combining
PI3K inhibitor with JAK2 inhibitors in the management
of MPNs. However, these pre-clinical studies are based
on cells carrying a single mutation (JAK2) and may not
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accurately represent the situation in vivo with multiple
mutations in the same clone. Development of in vitro
assays with patient samples can overcome this limitation.
Development of mice models with complex mutations
that more closely mimic the patient mutation profiles
are likely to be more informative in pre-clinical evalua-
tions for drug combinations.
Conclusions
Discovery of the genetic mutations and understanding of
the signaling pathways involved the pathogenesis of
MPNs has led to the rational development of small mol-
ecule inhibitors that target the signaling intermediaries.
Identification of novel mutations in CALR in ET and
PMF patients with non-mutated JAK2 and MPL is an-
other important step in this field but the mechanistic de-
tails of how CALR contributes to the development of
MPN remains to be elucidated. Additionally, the mo-
lecular drivers of aberrant signaling in Ph-ve MPN pa-
tients that do not have mutations in JAK2, MPL, KIT,
CALR and CSF3R need to be identified. Though the role
of deregulated cytokine signaling has become clearer, the
functional significance of mutations in epigenetic regula-
tors that are frequently associated with MPNs is largely
unknown. However it is clear that PI3K pathway plays a
pivotal role in the pathogenesis of many of these Ph-ve
MPNs and holds promise for future informed thera-
peutic decisions. Though we are still far from finding a
cure, the promising results from preclinical and clinical
testing indicate that co-targeting of the PI3K pathway
along with the tyrosine kinases and/or epigenetic regula-
tors will significantly improve the response and lead to
better disease management. Since a large number of in-
hibitors are already in safety and efficacy trials for solid
tumors and other hematological malignancies, transition
from lab to the clinic for MPN will be a rapid process.
The major challenge with PI3K inhibitors will involve
the management of the feedback inhibitory loops which
are also likely to be compromised by these inhibitors.
With improved understanding of the regulatory mecha-
nisms and crosstalk between different signaling path-
ways, it may be possible to overcome the resistance due
to activation of compensatory pathways. Future progress
will involve a more personalized approach and thera-
peutic strategies based on the presence of specific gen-
etic and molecular abnormalities in MPN patients.
Better in vitro and in vivo models that mimic the com-
plexity in the mutations observed in the patients would
more accurately predict the efficacy of drugs. Improve-
ments in patient selection and rational combinations tar-
geting multiple pathways that synergize with PI3K
signaling module is more likely to be successful in realiz-
ing the full potential of this promising class of inhibitors.
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